Global Gene Therapy Market Outlook, Trend and Opportunity Analysis, Competitive Insights, Actionable Segmentation & Forecast 2024

Industry : Healthcare Date : April 19th, 2018
Tutorials Get 15% Discount on First Report

The global gene therapy market is expected to grow significantly from USD 215.0 million in 2017 to USD 558.7 million in 2024, at a CAGR 14.6% from 2018 to 2024. This growth is attributed to the growing number of clinical trial and increasing funding for research and development activities. Moreover, increasing awareness regarding gene therapy and growing number of chronic and genetics diseases are propelling the growth of the industry. The years used for the assessment are as follows:

Historical year: 2014, 2015, 2016

Base year: 2017

Forecast period: 2018 – 2024

RESEARCH METHODOLOGY

The research and analysis is based on the data and information obtained from various primary and secondary sources. The data obtained is validated by interacting with the companies of the concerned domain. The steps involved in the research methodology are;

  • Obtaining historical data of the market based on news, articles, publications, annual reports, white papers, surveys, and other secondary sources
  • Interacting with key opinion leaders of the market and developing data points based on interaction with them
  • Study of past trends in the market and their year on year Impact on the market size and share
  • Analyzing the collected data points
  • Bridging the data points to calculate the total global gene therapy market and its various segments
  • Anticipating potential risks
  • Analyzing market forces such as drivers, restraints, and opportunities to assess new growth areas for the global gene therapy market
  • Finalizing the overall size and share of the global gene therapy market

OBJECTIVES:

  • To analyze market trends, opportunities, drivers, and restraints associated with the global gene therapy market
  • To study market response with respect to the mergers and acquisitions in the industry
  • To profile key companies operating in the global gene therapy market and provide their competitive landscape

MARKET SCOPE

The research scope for Global Gene Therapy Market is as follows:

By Types

  • Germline Gene Therapy
  • Somatic Gene Therapy

By Vectors Type

  • Viral Vectors
    • Adeno Associated Virus
    • Herpes Simplex Virus
    • Retroviruses
    • Lentiviruses
    • Poxvirus
    • Vaccinia Virus
    • Adenoviruses
    • Others
  • Non-Viral Vectors
    • Gene Gun
    • Lipofection
    • Naked/Plasmid Vectors
    • Electroporation
    • Others

By Application

  • Infections Disorders
  • Genetic Disorders
  • Rare Diseases
  • Oncology Diseases
  • Cardiovascular Disorders
  • Diabetes Mellitus
  • Neurological Disorders
  • Other Diseases

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

The global gene therapy market is expected to grow significantly from USD 215.0 million in 2017 to USD 558.7 million in 2024, at a CAGR 14.6% from 2018 to 2024. This growth is attributed to the growing number of clinical trial and increasing funding for research and development activities. Moreover, increasing awareness regarding gene therapy and growing number of chronic and genetics diseases are propelling the growth of the industry.

On the basis of vectors type, the viral vectors hold the major share of the market in 2017. Based on application, the oncology diseases segment hold the major share of market due to growing number of cancer patients, as well as  increasing number of research and development activities in this segment.

North America has witnessed to hold the maximum share of the global market and the trend is likely to continue over the forecast period. The growth is attributed to in this region growing number of peoples suffering from chronic diseases, and increasing number of clinical trials. Europe holds the second largest market share of gene therapy in 2017, owing to growing number of therapies approval as well as favorable government policies in this region. Asia-Pacific region is anticipated to witness the highest CAGR over the forecasted period.

Key players in global gene therapy market are Spark Therapeutics, Inc.; Bluebird bio, Inc.; ViroMed Co., Ltd.; Sanofi ; Advantagene, Inc.; Vical Inc.; Oxford BioMedica; Human Stem Cells Institute; GlaxoSmithKline plc.; Novartis AG; AveXis, Inc.; Editas Medicine; REGENXBIO Inc.

TABLE OF CONTENTS

CHAPTER 1. Market Scope and Methodology

1.1. Research methodology

1.2. Research scope & assumptions

1.3. List of data sources

CHAPTER 2. Executive Summary

2.1. Gene Therapy- Market Snapshot

CHAPTER 3. Industry Analysis

3.1. Market definition

3.2. Market segmentation

3.3. Key findings of the global gene therapy market

3.4. Value chain analysis

3.5. Market opportunities & trends

3.5.1. Market driver analysis

  3.5.1.1. Growing demand for treatment and cure a wide range of genetic diseases

  3.5.1.2. Increasing research and development activities

  3.5.1.3. Growing awareness among people

  3.5.1.4. Government and private funding support to the gene therapy

3.5.2. Market restraint analysis

  3.5.2.1. Multigene disorders

  3.5.2.2. High cost of genetic therapy treatment

3.5.3. Industry Analysis-Porters five forces of analysis

CHAPTER 4. Competitive Outlook

4.1. Competitive aanalysis

4.2. Competitive factors

4.3. Strategies adopted

CHAPTER 5. Global Gene Therapy Market Size and Forecast (2014 – 2024)

5.1. Global Gene Therapy Market, By Type

5.1.1. Germline Gene Therapy

5.1.2. Somatic Gene Therapy

5.2. Global Gene Therapy Market, By Vectors Type

5.2.1. Viral Vectors

  5.2.1.1. Adeno Associated Virus

  5.2.1.2. Herpes Simplex Virus

  5.2.1.3. Retroviruses

  5.2.1.4. Lentiviruses

  5.2.1.5. Poxvirus

  5.2.1.6. Vaccinia Virus

  5.2.1.7. Adenoviruses

  5.2.1.8. Others

5.2.2. Non-Viral Vectors

           5.2.2.1. Gene Gun

   5.2.2.2. Lipofection

   5.2.2.3. Naked/Plasmid Vectors

   5.2.2.4. Electroporation

   5.2.2.5. Others

5.3. Global Gene Therapy Market, By Application

5.3.1. Infections Disorders

5.3.2. Genetic Disorders

5.3.3. Rare Diseases

5.3.4. Oncology Diseases

5.3.5. Cardiovascular Disorders

5.3.6. Diabetes Mellitus

5.3.7. Neurological Disorders

5.3.8. Other Diseases

5.4. Global Gene Therapy Market, By Region

5.4.1. North America

5.4.2. Europe

5.4.3. Asia-Pacific

5.4.4. Rest of the World (RoW)

CHAPTER 6. Global Gene Therapy Market, By Geography

6.1. North America Gene Therapy Market

6.1.1. North America Gene Therapy Market, By Type (USD Million)

6.1.2. North America Gene Therapy Market, By Vectors Type (USD Million)

6.1.3. North America Gene Therapy Market, By Application (USD Million)

6.1.4. North America Gene Therapy Market, By Country

  6.1.4.1. U.S.

  6.1.4.2. Canada

  6.1.4.3. Mexico

6.2. Europe Gene Therapy Market

6.2.1. Europe Gene Therapy Market, By Type (USD Million)

6.2.2. Europe Gene Therapy Market, By Vectors Type (USD Million)

6.2.3. Europe Gene Therapy Market, By Application (USD Million)

6.2.4. Europe Gene Therapy Market, By Country

   6.2.4.1. Germany

   6.2.4.2. France

   6.2.4.3. U.K.

   6.2.4.4. Italy

   6.2.4.5. Spain

  6.2.4.6. Rest of Europe

6.3. Asia-Pacific Gene Therapy Market

6.3.1. Asia-Pacific Gene Therapy Market, By Type (USD Million)

6.3.2. Asia-Pacific Gene Therapy Market, By Vectors Type (USD Million)

6.3.3. Asia-Pacific Gene Therapy Market, By Application (USD Million)

6.3.4. Asia-Pacific Gene Therapy Market, By Country

  6.3.4.1. China

  6.3.4.2. Australia

  6.3.4.3. Japan

  6.3.4.4. South Korea

  6.3.4.5. India

  6.3.4.6. Rest of Asia-Pacific

6.4. Middle East and Africa Gene Therapy Market

6.4.1. Middle East and Africa Gene Therapy Market, By Type (USD Million)

6.4.2. Middle East and Africa Gene Therapy Market, By Vectors Type (USD Million)

6.4.3. Middle East and Africa Gene Therapy Market, By Application (USD Million)

6.4.4. Middle East and Africa Gene Therapy Market, By Region

  6.4.4.1. Middle East and Africa (MEA)

  6.4.4.2. Latin America

CHAPTER 7. Key Players and Strategic Developments

7.1. Spark Therapeutics, Inc.

7.1.1. Business Overview

7.1.2. Product and Service Offering

7.1.3. Financial Overview

7.1.4. Strategic Developments

7.2. Bluebird bio, Inc.

7.2.1. Business Overview

7.2.2. Product and Service Offering

7.2.3. Financial Overview

7.2.4. Strategic Developments

7.3. ViroMed Co., Ltd.

7.3.1. Business Overview

7.3.2. Product and Service Offering

7.3.3. Financial Overview

7.3.4. Strategic Developments

7.4. Sanofi

7.4.1. Business Overview

7.4.2. Product and Service Offering

7.4.3. Financial Overview

7.4.4. Strategic Developments

7.5. Advantagene, Inc.

7.5.1. Business Overview

7.5.2. Product and Service Offering

7.5.3. Financial Overview

7.5.4. Strategic Developments

7.6. Vical Inc.

7.6.1. Business Overview

7.6.2. Product and Service Offering

7.6.3. Financial Overview

7.6.4. Strategic Developments

7.7. Oxford BioMedica

7.7.1. Business Overview

7.7.2. Product and Service Offering

7.7.3. Financial Overview

7.7.4. Strategic Developments

7.8. Human Stem Cells Institute

7.8.1. Business Overview

7.8.2. Product and Service Offering

7.8.3. Financial Overview

7.8.4. Strategic Developments

7.9. GlaxoSmithKline plc.

7.9.1. Business Overview

7.9.2. Product and Service Offering

7.9.3. Financial Overview

7.9.4. Strategic Developments

7.10. Novartis AG

7.10.1. Business Overview

7.10.2. Product and Service Offering

7.10.3. Financial Overview

7.10.4. Strategic Developments

7.11. AveXis, Inc.

7.11.1. Business Overview

7.11.2. Product and Service Offering

7.11.3. Financial Overview

7.11.4. Strategic Developments

7.12. Editas Medicine

7.12.1. Business Overview

7.12.2. Product and Service Offering

7.12.3. Financial Overview

7.12.4. Strategic Developments

7.13. REGENXBIO Inc.

7.13.1. Business Overview

7.13.2. Product and Service Offering

7.13.3. Financial Overview

7.13.4. Strategic Developments

7.14. Abbreviation

Global Gene Therapy Market Outlook, Trend and Opportunity Analysis, Competitive Insights, Actionable Segmentation and Forecast 2024